ABSTRACT In a six-year survey 10(0.15%) of 6849 patients with European names and 31 (1.0%) of 3079 patients with non-European names yielded cultures of Mycobacteriumn tuberculosis that were resistant to rifampicin. Only two of each group had organisms resistant to rifampicin alone. Resistance to one or more other antituberculous drugs was found in eight of the European and 29 of the non-European group. Two patients in each group were known to have received treatment for the first time in the United Kingdom; 17 of the non-Europeans were known to have been treated abroad; precise information was not available for the other 12. The overall six-year incidence of patients with rifampicin-resistant M tuberculosis was only 0.41%. The very low incidence among Europeans is probably the result of stricter regimens than are possible in some other areas.
All cultures of Mycobacterium tuberculosis received and identified in this laboratory since the beginning of 1975 have been tested for sensitivity to rifampicin as well as other antituberculous drugs. Experience suggested that resistance to rifampicin was uncommon and confined to certain groups of patients. We thought therefore that a retrospective analysis of the results obtained over a period of six years might be informative.
Methods
From 1 January 1975 to 31 December 1980 cultures were received from 9928 patients who were new to the laboratory register. Of Tests were repeated on all cultures found to be resistant when first examined. More than one culture was examined from most patients over the six years.
Results
Ten out of 6849 (0.15%) patients with European names and 31 out of 3079 (1.0%) with nonEuropean names had rifampicin-resistant strains of M tuberculosis, the overall resistance rate in the 9928 patients being 0-41%. Eight patients in the European group and 29 in the non-European group were resistant to at least one other drug (table 1) . Only two of the non-European patients with rifampicin-resistant strains were known to have been treated in the United Kingdom, but all 10 of the European group were (table 2). Only two patients in the European group acquired resistance during the period of the survey. Both had been treated with isoniazid and ethambutol, and both yielded isoniazid-resistant as well as rifampicin-resistant organisms. Both patients were described by their physicians as "non-compliant." The two patients with non-European names who acquired their resistance in Britain arrived with histories of treatment with several drugs, including rifampicin. One had tubercle bacilli that were resistant to streptomycin and isoniazid; the other had organisms resistant to streptomycin, isoniazid, p-aminosalicylic acid, and ethambutol. Both were treated in Britain with several drugs, including rifampicin, and resistance emerged within a year.
Resistance to rifampicin was accompanied by resistance to one or more other drugs in all but two cultures from both the European and the nonEuropean group. Siddiqi et al.,' writing from Pikistan, examined cultures from 1063 patients and found that all of the 21 that were resistant to rifampicin were also resistant to isoniazid, and 17 of them were resistant to other antituberculous agents as well. A further 34 strains, obtained from the United States, were resistant to both rifampicin and isoniazid. Thus resistance to rifampicin alone appears to be uncommon. Nineteen of the 31 patients with non-European names and rifampicinresistant organisms (table 2) had a history of treatment with rifampicin and other antituberculous drugs before they arrived in the United Kingdom. Precise information about the other 12 was lacking, but as they were visitors or recent immigrants we may assume that they had been treated outside Europe.
These results confirm opinions expressed by physicians that successful treatment with rifampicin, as with other drugs, is associated with strict regimens and the prevention of self-medication. This is possible in developed countries, but often very difficult to achieve in the third world. 
